A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model
Taken together, these data characterize a broad anti-tumor immune cell response to oncolytic VSV-NDV therapy and suggest that CD8<sup>+</sup> T cells play a decisive role in therapeutic outcome, which supports the further development of this chimeric vector as a multimechanistic immunotherapy for solid cancers.
Authors
- Gabriela M. Wiedemann (ORCID: https://orcid.org/0000-0001-6138-9791)
- Jennifer Altomonte (ORCID: https://orcid.org/0000-0003-1079-3633)
- Janina Marek
- Victoria Neumeyer (ORCID: https://orcid.org/0000-0003-2659-3644)
- Nina Hartmann
- Sonja Glauß
- Lorenz Hanesch
Institutions
- TUM Klinikum (DE)
- Technical University of Munich (DE)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-06
- DOI
- https://doi.org/10.3390/cancers16193405
- Citations
- 8
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.40
Funders
- Wilhelm Sander-Stiftung
- European Research Council